Company
PharmaDrug Inc
CNSX:BUZZ
PharmaDrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. The company owns 51% of Sairiyo Therapeutics, a biotech company specialising in researching and reformulating established natural medicines to bring them through clinical trials and the associated regulatory approval process in the US and Europe.
66 stories · page 1 of 4
PharmaDrug wraps up key step in production of oral bioavailable version of its oncology and infectious disease drug cepharanthine
Completion of this lot advances the company's efforts to support pre-clinical and clinical development, including the commencement of Phase 2 clinical studies, for parallel indications in oncology and infectious disease
PharmaDrug aims to file provisional patent for treatment of glaucoma in the fourth quarter this year
The firm said it has selected a final lead drug candidate from a short list of six DMT analogues and intends to submit the patent in the fourth quarter this year
PharmaDrug completes significant groundwork to support multi-kilogram production of cepharanthine-2HCL drug
PharmaDrug intends to develop and commercialize PD-001 as an oral antiviral treatment for mild to moderate SARS-CoV-2 infections, plus esophageal and prostate cancers
PharmaDrug closes sale of German cannabis assets to Khiron Life Sciences
With the sale of its German asset complete, PharmaDrug said it continues to advance PD-001, its patented version of cepharanthine, towards potential FDA clinical trials on both the oncology and antiviral fronts